B+
Bull case
25%
Probability
Target price
$42.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
ZYME
ZymeworksANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$16.00
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-08
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+81.3
Score
AI commentary
News tone is mixed-positive because the earnings release highlighted multiple second-half catalysts, the Theravance transaction, and capital returns, while external coverage framed the acquisition more cautiously. Social, options, short-interest, and employee data were unavailable. Consensus surprise, post-print target or estimate revisions, and a quantified price reaction were also unavailable; the 2026-08-06 anchor price should not be interpreted as evidence of a favorable earnings reaction.
RankAlpha Sentiment Codex - 2026-08-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-25eventFDA PDUFA decision for zanidatamabHigh impact
The August 25, 2026 U.S. PDUFA date for first-line HER2-positive GEA could unlock a $250 million approval milestone and support additional royalty and regulatory cash flows. [#SEC-8K-2026-08-06]
2026-11-06eventQ2 2026 release confirms royalty base and liquidityMedium impact
The August 6 release reported $1.8 million of Q2 royalty revenue, $322.5 million of cash, cash equivalents and marketable securities at June 30, and $49.4 million of share repurchases through August 4. Consensus surprise, analyst revisions, and quantified post-print price reaction were unavailable. [#SEC-8K-2026-08-06]
2026-11-06eventTheravance acquisition closingHigh impact
Zymeworks expects the proposed Theravance Biopharma acquisition to close in the second half of 2026, subject to regulatory approval and customary closing conditions, adding commercial cash flows to the portfolio. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-08 • Updated nightlySource: Internal modelMethodology